Today: 30 June 2026
Browse Category

NASDAQ:OMER 15 October 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.” The spark was the U.S. FDA approval of YARTEMLEA® as the first and only therapy indicated for hematopoietic stem cell transplant–associated thrombotic microangiopathy—a dangerous complication that can follow stem cell transplantation. Omeros says it is finalizing preparations for a U.S. launch in January 2026, with reimbursement infrastructure already in motion. Omeros Corporation
25 December 2025
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see. As of 2:35 p.m. ET in after-hours trading on Wednesday, Dec. 24, 2025, OMER stock traded around $15.36, up about $6.59 from the prior close, after swinging through a wide intraday range on heavy volume.
24 December 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 to $10.42 by Oct 15 closeinvestor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal. Trading volume was staggering: Benzinga reports ~89.2 million shares traded during the rallybenzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen just days priorts2.techbenzinga.com. The rapid rise snapped years of flat to depressed trading: OMER spent most of 2025 in the $4–5 range until this weekinvestor.omeros.com. The stock’s volatility had been well-known; analysts caution that such biotech names swing wildly on news. As one tech-stock analysis noted, “traders are upbeat” but warned Omeros has “historically tight cash” and high R&D coststs2.tech. In short, Omeros is back in spotlight, but the same factors that make it promising also make it risky.
16 October 2025
···
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

On Oct. 15, Novo Nordisk and Omeros announced a landmark deal licensing zaltenibart, Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not an outright acquisition – and is expected to close in Q4 2025, after which Novo will launch a global Phase 3 trial in PNH and possibly other complement disordersts2.techreuters.com. Novonordisk’s CSO Martin Lange praised zaltenibart’s “novel mode of action” and potential advantages over existing complement therapiesinvestor.omeros.com. Omeros CEO Gregory Demopulos welcomed the partnership, saying he was “pleased to enter into this agreement with Novo Nordisk” and expects Novo’s global reach to “unlock the potential” of zaltenibartinvestor.omeros.com. According to ts2.tech, Omeros executives believe the deal “validates their research and funds further trials”ts2.tech. In effect, the transaction injects cash into Omeros and confirms interest in its drug pipeline.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific Officer Martin Holst Lange described zaltenibart as having a “novel mode of action” with potential advantages over existing treatments Marketscreener. Omeros CEO Gregory Demopulos said he expects Novo’s global reach to “unlock the potential” of zaltenibart Marketscreener. The press release notes that Omeros keeps certain unrelated MASP-3 assets and will now concentrate on getting its lead MASP-2 antibody, narsoplimab, approved Marketscreener.
15 October 2025
···

Stock Market Today

  • US Stock Futures Slip Before US-Iran Talks, Tech Stocks Lead Gains
    June 29, 2026, 11:36 PM EDT. U.S. stock futures slipped early with US-Iran talks set to take place in Doha. S&P 500 futures were off 0.20%, Dow futures fell 0.15% and Nasdaq 100 futures lost 0.25%. This drop comes after Monday's close where the S&P 500 added 1.18%, the Nasdaq jumped 2.07% for its best quarter since 2020, and the Dow Jones Industrial Average finished above 52,000 for a record. Tech names powered the move, with Alphabet up close to 5%. Amazon, Meta and Nvidia also gained. Semiconductors tracked higher as chip ETFs rallied, even with some worries on how long AI demand can keep driving the moves. Oil eased a bit with Middle East tensions cooling, but stayed above $70.
Go toTop